mardi 5 février 2019

Onco Actu du 5 février 2019


1. BIOLOGIE



Seven international genomic data initiatives named GA4GH Driver Projects [GA4GH]











1.1 BIOLOGIE - GÈNES



Esophageal Cancer Analysis Reveals Driver, Prognostic Alterations [Genome Web]











Downloading the genetic rules of cancer [Cancer Research UK]










Mapping oesophageal cancer genes leads to new drug targets [Cancer Research UK]











1.4 BIOLOGIE - TECHNOS



A New Toolkit For Studying How "PARP" Activity Boosts Cancers [Johns Hopkins]











2. ETIOLOGIE



Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities [EMA]











2.7 ETIOLOGIE - OBÉSITÉ



Obesity-Related Cancers Rising in Young Adults in the U.S. [ACS]










Statement From American Society of Clinical Oncology (ASCO) President Monica M. Bertagnolli, MD, FACS, FASCO, on New Findings on Obesity and Cancer [ASCO]











Obesity Tied to Higher Cancer Rates in Younger People [NY Times]











Obesity-related cancers rising in U.S. young adults [Reuters]











3.1 PRÉVENTION - TABAC



Smokeless tobacco: 5 common questions about ‘heat not burn’ products answered [Cancer Research UK]











Cancer patients may need longer support to quit smoking [Reuters]











3.3 PRÉVENTION - VACCINS



“HPV vaccination is safe, effective, and critical for eliminating cervical cancer” [IARC]










4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Five warning signs of overdiagnosis [The Conversation]










A guide to systematic review and meta-analysis of prognostic factor studies [BMJ]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



The NY Times is far too worried about 23andMe's genetic test [Genomics, Medicine, and Pseudoscience]











Why You Should Be Careful About 23andMe’s Health Test [NY Times]










4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



Thousands of cervical screening samples are waiting to be tested, says report [Cancer Research UK]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Drug target identified for chemotherapy-resistant ovarian, breast cancer [WUSTL]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Immuno-oncology player TCR2 Therapeutics tees up for $80M IPO [Fierce Biotech]











5.12.6 IMMUNOTHÉRAPIES - AMM



Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma [NCI]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Merck analysts to CEO: What’s so great about your pipeline beyond Keytruda? [Fierce Pharma]











Does Merck need more than Keytruda? [Biopharma Dive]











5.2 PHARMA



Biotech Crunch time for ImmunoGen as phase 3 readout looms for lead ADC [Fierce Biotech]











Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment [Roche]











Roche moves to broaden Kadcyla use in biosimilar defense [Reuters]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



Does Bristol-Myers Squibb’s new activist investor want to stall its Celgene buyout? [Fierce Pharma]











5.2.3 PHARMA - ÉCONOMIE



Novartis spend on digital and data ‘in the 100s of millions’ [Pharma Times]











Rep. Ocasio-Cortez and Where Drugs Come From [In The Pipeline]











5.3 TRAITEMENTS - FDA, EMA, NICE...



EMA Updates Brexit Guidance [RAPS]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations [Pfizer]











CHMP recommends EU approval of Roche’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer [Roche]











2018 Drug Approvals: A Closer Look [In The Pipeline]










Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019 [EMA]










EMA Recommends Granting a Marketing Authorisation for Dacomitinib [ESMO]











6.1 OBSERVATION



No overall increased risk of cancer in children born after fertility treatment [European Society of Human Reproduction and Embryology]










6.10.1 POLITIQUES (USA)



Congress wants these 7 drug company CEOs to testify about prices [STAT]











6.12 ETHIQUE



Carlo Croce loses a round in legal bid to be reinstated as dep’t chair [Retraction Watch]











6.6 PUBLICATIONS



Opinion: “Plan S” falls short for society publishers—and for the researchers they serve [PNAS]










6.9 CONTROVERSES



Cancer Cures and the Importance of Communicating Responsibly [Xconomy]











The downside of inflammatory news about cancer [STAT]











The modern tragedy of fake cancer cures [STAT]